Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell, Lymphoma, Presented at ASH 2018

 Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell, Lymphoma, Presented at ASH 2018

Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell, Lymphoma, Presented at ASH 2018

Shots:

  • The ZUMA-1 trial involves assessing of Yescarta in patients with refractory large B-cell lymphoma for a duration of two years
  • ZUMA-1 trial results (N=101): OR 83%; CR 58%; median follow up @27.1, 24 mos. (39%, 93% remain in response); mDOR 11.1 mos.; with no new safety signals observed
  • Yescarta (axicabtagene ciloleucel) is novel CAR T therapy approved by FDA for 2L+ r/r large B-cell lymphoma. The US PI involves a box warning with the usage of Yescarta leading to Cytokine Release Syndrome (CRS) & Neurologic toxicities

Click here to read full press release/ article | Ref: Kite | Image: Eideard

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post